



University of Dundee

Anti-trypanosomatid drug discovery

Field, Mark; Horn, David; Fairlamb, Alan H.; Ferguson, Michael A. J.; Gray, David W.; Read, Kevin D.; De Rycker, Manu; Torrie, Leah S.; Wyatt, Paul G.; Wyllie, Susan; Gilbert, Ian

Published in: Nature Reviews Microbiology

DOI: 10.1038/nrmicro.2016.193

Publication date: 2017

Document Version Peer reviewed version

Link to publication in Discovery Research Portal

Citation for published version (APA): Field, M. C., Horn, D., Fairlamb, A. H., Ferguson, M. A. J., Gray, D. W., Read, K. D., ... Gilbert, I. H. (2017). Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need. Nature Reviews Microbiology, 15(4), 217-231. DOI: 10.1038/nrmicro.2016.193

General rights


Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
You may not further distribute the material or use it for any profit-making activity or commercial gain.
You may freely distribute the URL identifying the publication in the public portal.

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Figure for Box 1




Trypanosoma brucei

Mammal

Amplification

Long slender



Compound structures for Table 1





Figure 1

Hit Lead Preclinical Clinical Registration				
Discovery of chemical start points using a variety of methods, including; Phenotypic (whole cell) screening, Screening against molecular targets, Modification of existing compounds.	Good manufact (GMP) scale up regulatory pract toxicology.	and good	Phase 4: Post market surveillance.	
Multi-parametric optimisation for potency, selectivity, physicochemical and pharmacokinetic properties and non-clinical safety properties.		Phase 1: Pharmacokinetics and tolerability in healthy human volunteers. Phase 2: Proof of concept in patients.		

Phase 2: Proof of concept in patients. Phase 3: Large efficacy and safety study in patients.

Figure 2



fexinidazole

SCYX-7158

VL-2098




Figure 3

